Effect of Angiotensin Peptides on PAI-1 Expression and Production in Human Adipocytes

Angiotensin (Ang) II is the active component of the renin-angiotensin-system (RAS), but its degradation products have also been shown to exhibit biological activity. This system, which mainly controls blood pressure and electrolyte homeostasis, was recently found to be completely expressed in human adipose tissue. The major determinant in the fibrinolytic system is the plasminogen activator inhibitor-1 (PAI-1). Both PAI-1 and components of the RAS are over-expressed in the obese state. We have recently shown that Ang II is able to induce PAI-1 expression and release via the AT₁-receptor in human fat cells in primary culture, and have provided the first evidence that two metabolites, Ang III and Ang IV, may have a similar stimulatory effect on PAI-1 release. We have now performed additional experiments to further characterize the role of the angiotensin peptides in the production of PAI-1. Ang III and Ang IV showed a time- and dose-dependent stimulation of PAI-1 protein release. Concomitantly, mRNA-levels were markedly elevated. Using specific receptor blockers, all angiotensin peptides seem to induce PAI-1 expression via the angiotensin receptor subtype 1. However, components of the renin-angiotensin-system seem to play an important role in the control of fibrinolysis in adipose tissue. We conclude that PAI-1 production by adipose tissue may contribute to the elevated thromboembolic risk in obesity.

Key-words:

Adipose Tissue - Angiotensin II - Fibrinolysis - Plasminogen Activator Inhibitor-1 - Renin-Angiotensin-System - Hypertension - Obesity

References

• 1 Vaughan D E. The renin-angiotensin-system and fibrinolysis.  Am J Cardiol. 1997;  79 2-14
• 2 Karlsson C, Lindell K, Ottosson M, Sjöström L, Carlsson B, Carlsson L M. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II.  J Clin Endocrinol Metab. 1998;  83 3925-3929
• 3 Schling P, Mallow H, Trindl A, Löffler G. Evidence for a local renin angiotensin system in primary cultured human preadipocytes.  Int J Obes Relat Metab Disord. 1999;  23 36-41
• 4 Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma A M. Co-expression of renin-angiotensin system genes in human adipose tissue.  J Hypertens. 1999;  17 555-560
• 5 Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity.  Obes Res. 2000;  8 337-341
• 6 Van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I, Bringman S, Arner P. The assotiation of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity.  Int J Obes Relat Metab Disord. 2000;  24 673-678
• 7 Hall J E, Brands M W, Henegar J R. Mechanisms of hypertension and kidney disease in obesity.  Ann N Y Acad Sci. 1999;  892 91-107
• 8 Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M, Ishigami T, Yabana M, Kihara M, Inoue S, Ishii M. Plasma angiotensinogen concentrations in obese patients.  Am J Hypertens. 1997;  10 629-633
• 9 Juhan-Vague I, Alessi M C. PAI-1, obesity, insulin resistance and risk of cardiovascular events.  Thromb Haemost. 1997;  78 1716-1722
• 10 Juhan-Vague J, Alessi M C. Fibrinolysis and risk of coronary artery disease.  Fibrinolysis. 1996;  10 127-136
• 11 Alessi M C, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease.  Diabetes. 1997;  46 860-867
• 12 Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals.  Diabetologia. 1998;  41 65-71
• 13 Gottschling-Zeller H, Birgel M, Röhrig K, Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture.  Metabolism. 2000;  49 666-671
• 14 Loskutoff D J, Samad F. The adipocyte and hemostatic balance in obesity: studies on PAI-1.  Arterioscler Thromb Vasc Biol. 1998;  18 1-6
• 15 Ridker P M, Gaboury C L, Conlin P R, Seely E W, Williams G H, Vaughan E D. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II.  Circulation. 1993;  87 1969-1973
• 16 Feener E P, Northrup J M, Aiello L P, King G L. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells.  J Clin Invest. 1995;  95 1353-1362
• 17 Vaughan D E, Lazos S A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.  J Clin Invest. 1995;  95 995-1001
• 18 Nishimura H, Tsuji H, Masuda H, Kasahara T, Yoshizumi M, Sugano T, Kimura S, Kawano H, Kunieda Y, Yano S, Nakagawa K, Kitamura H, Nakahara Y, Sawada S, Nakagawa M. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells.  Thromb Haemost. 1999;  82 1516-1521
• 19 Kerins D M, Hao Q, Vaughan D E. An Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.  J Clin Invest. 1995;  96 2515-2520
• 20 Swanson G N, Hanesworth J M, Sardinia M F, Coleman J KM, Wright J W, Hall K L, Miller-Wing A V, Stobb J W, Cook V I, Harding E C, Harding J W. Discovery of a distinct binding site for angiotensin II (3 - 8).  Regul Pept. 1992;  40 409-419
• 21 Perodin J, Bouley R, Escher E, Assimomytis N, Magafa V, Maness-Zoupa E, Theodoropoulos D, Cordopatis P. Angiotensin II analogues with sulphur-containing side-chains in position 5. A structure-activity relationship study.  Arzneimittelforschung. 2000;  50 526-529
• 22 Skurk T, Lee Y .-M., Röhrig K, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension; manuscript accepted for publication
• 23 Tabrizchi R, Moore G J, Pang C C. [Sar¹, Ile⁷]-angiotensin III, a new selctive antagonist of the pressor effect of angiotensin III in conscious rats.  Life Sci. 1988;  43 537-543
• 24 A Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, Pfeiffer E F. Promoting effects of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium.  J Clin Invest. 1989;  84 1663-1670
• 25 Labinjoh C, Newby D E, Dawson P, Johnston N R, Ludlam C A, Boon N A, Webb D J. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man.  Cardiovasc Res. 2000;  47 707-714
• 26 Birgel M, Gottschling-Zeller H, Röhrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes.  Arterioscler Thromb Vasc Biol. 2000;  20 1682-1687
• 27 Bloem L J, Manatunga A K, Tewksbury D A, Pratt H J. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children.  J Clin Invest. 1995;  95 948-953
• 28 Crandall D L, Herzlinger H E, Saunders B D, Armellino D C, Kral J G. Distribution of angiotensin II receptors in rat and human adipocytes.  J Lipid Res. 1994;  35 1378-1385
• 29 Vaughan D E, Rouleau J L, Ridker P M, Arnold J M, Menapace F J, Pfeffer M A. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.  Circulation. 1997;  96 442-447